DiaMedica Therapeutics (NASDAQ:DMAC) Cut to “Sell” at Wall Street Zen

Wall Street Zen downgraded shares of DiaMedica Therapeutics (NASDAQ:DMAC – Free Report) from a hold rating to a sell rating in a research report sent to investors on Saturday,Wall Street Zen reports.

Several other research firms also recently issued reports on DMAC. Weiss Ratings reissued a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research report on Thursday, October 15th. HC Wainwright restated a “buy” rating and issued a $12.00 target price on shares of DiaMedica Therapeutics in a research note on Tuesday, August 11th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $12.00.

View Our Latest Report on DMAC

DiaMedica Therapeutics Trading Down 5.2%

Shares of DiaMedica Therapeutics stock opened at $8.33 on Friday. DiaMedica Therapeutics has a 12-month low of $5.24 and a 12-month high of $11.00. The firm has a market capitalization of $449.24 million, a price-to-earnings ratio of -10.96 and a beta of 0.95. The firm’s 50 day simple moving average is $8.24 and its two-hundred day simple moving average is $7.20.

DiaMedica Therapeutics (NASDAQ:DMAC – Get Free Report) last posted its quarterly earnings results on Thursday, November 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.21). On average, sell-side analysts predict that DiaMedica Therapeutics will post -0.84 EPS for the current fiscal year.

Institutional Investors Weigh In On DiaMedica Therapeutics

A number of large investors have recently bought and sold shares of DMAC. Cetera Investment Advisers purchased a new position in DiaMedica Therapeutics during the 3rd quarter worth approximately $280,000. AWM Investment Company Inc. acquired a new stake in DiaMedica Therapeutics during the 2nd quarter valued at approximately $253,000. Tocqueville Asset Management L.P. acquired a new stake in DiaMedica Therapeutics during the 3rd quarter valued at approximately $332,000. Bank of America Corp DE boosted its holdings in shares of DiaMedica Therapeutics by 62.5% in the 1st quarter. Bank of America Corp DE now owns 42,768 shares of the company’s stock valued at $290,000 after acquiring an additional 16,446 shares during the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in shares of DiaMedica Therapeutics in the 1st quarter valued at $356,000. Hedge funds and other institutional investors own 10.12% of the company’s stock.

About DiaMedica Therapeutics

(Get Free Report)

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company developing treatments for serious diseases, with a focus on preeclampsia and neurological conditions. Its lead candidate, DM199 (rinvecalinase alfa), is a recombinant form of human tissue kallikrein-1, an enzyme involved in regulating blood flow. DiaMedica is investigating DM199 for acute ischemic stroke and preeclampsia; it remains an investigational drug and is not approved for commercial use. The company is headquartered in Minneapolis, Minnesota, and conducts clinical development of its therapies.

See Also

Receive News & Ratings for DiaMedica Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaMedica Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.